Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line FOLFIRI and Bevacizumab in Patients With Advanced Colorectal Cancer Prospectively Stratified According to Serum LDH

NCT01853813 is registered in ClinicalTrials.gov with Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente as lead sponsor.

NCT NCT01853813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01853813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line FOLFIRI and Bevacizumab in Patients With Advanced Colorectal Cancer Prospectively Stratified According to Serum LDH
Lead sponsor
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2013
Completion date
July 31, 2015
Enrollment
85 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer stage ii